Prostate cancer patients treated with the widely prescribed diabetes drug metformin showed elevated blood levels of N-lactoyl-phenylalanine, or Lac-Phe, a metabolite normally produced during vigorous exercise. The finding, drawn from a subset of a randomized phase 2 clinical trial, raises the possibility that metformin could partially replicate metabolic benefits of physical activity in patients whose treatment side effects make regular workouts difficult. The research does not claim metformin can replace exercise, but it opens a new line of inquiry into how a cheap, generic medication might ease the metabolic burden of hormone therapy.
What is verified so far
The central result comes from targeted UHPLC-MS/MS profiling of blood samples collected during the BIMET-1 trial. BIMET-1 is a randomized phase 2 study of bicalutamide with or without metformin in men with recurrent prostate cancer, described in detail in the publicly available trial report. The study enrolled overweight or obese men experiencing biochemical recurrence of prostate cancer and randomly assigned them to receive bicalutamide alone or bicalutamide plus metformin, with eligibility criteria, dosing schedules, and outcome measures including PSA response metrics and tolerability.
Researchers then profiled a subset of available sera from that trial using mass spectrometry. Their analysis, published in EMBO Molecular Medicine, found that metformin-treated patients had higher circulating Lac-Phe compared to those on bicalutamide alone. The underlying figure-level data, including Lac-Phe and lactate measurements across patient subsets, have been deposited at the European Bioinformatics Institute, allowing independent verification of the quantitative results and cross-checking of the metabolite patterns reported in the paper.
Why does Lac-Phe matter? A 2022 paper in Nature first identified this molecule as an exercise-induced circulating metabolite that suppresses feeding and obesity in experimental systems. In that work, the metabolite was synthesized from lactate and phenylalanine, two molecules that spike during intense physical activity, and higher Lac-Phe levels were linked to reduced food intake and improved metabolic parameters in animal models. Those findings established Lac-Phe as a plausible mediator of some exercise-associated metabolic effects, at least under controlled laboratory conditions.
A separate study published in Nature Metabolism confirmed that metformin and feeding increase Lac-Phe levels in humans, along with broader N-lactoyl amino acids in serum. That work included metabolomics methodology and cohort descriptions linking Lac-Phe levels to metformin measurements and feeding state, showing that the drug and nutritional status can modulate this exercise-linked metabolite outside of a formal exercise setting. Together, these findings provide a mechanistic bridge between metformin exposure, Lac-Phe production, and known metabolic pathways.
Investigators at the University of Miami Miller School of Medicine, who led the new analysis, have been explicit about its boundaries. Institutional communications from the Sylvester Comprehensive Cancer Center emphasize that the study does not offer a pill that replaces exercise. Instead, the clinical motivation centers on the metabolic strain that hormone therapy imposes on prostate cancer patients, which often limits their ability to exercise. If metformin can raise an exercise-linked metabolite in these patients, it could offer a partial metabolic buffer during treatment, potentially complementing but not substituting for physical activity when patients are able to be active.
What remains uncertain
Several gaps separate this finding from clinical action. The EMBO Molecular Medicine analysis profiled a subset of BIMET-1 participants, not the full trial cohort. Subset analyses carry inherent limitations: smaller sample sizes reduce statistical power, and the patients whose sera were available may not perfectly represent the broader enrolled population. No publicly available breakdown of the specific patient demographics or tolerability metrics for this subset has been identified beyond what the parent trial publication reports for the full cohort, so it is difficult to know whether the metabolomics sample is skewed toward particular age groups, comorbidities, or treatment responses.
More critically, no direct evidence yet links higher Lac-Phe levels to improved cancer outcomes in these patients. The BIMET-1 trial measured PSA response and tolerability as its primary endpoints, but the Lac-Phe analysis is a secondary metabolomic investigation layered on top of that framework. Whether the Lac-Phe increase translates into meaningful weight management, reduced fatigue, or slower disease progression has not been tested in a prospective design. The connection between Lac-Phe and appetite suppression was established in experimental models, and while the human data from the Nature Metabolism study confirm that metformin raises Lac-Phe in people, no trial has yet measured whether that elevation changes body composition or energy balance in prostate cancer patients specifically.
There is also no published exercise intervention trial in prostate cancer patients that directly measures Lac-Phe changes, which means researchers cannot yet compare the magnitude of metformin-driven Lac-Phe elevation against what structured physical activity would produce in the same population. The biosynthesis pathway linking lactate and phenylalanine to Lac-Phe has been described in general human physiology, but whether prostate cancer metabolism or hormone therapy alters that pathway remains an open question. Without those comparative data, it is premature to label metformin an “exercise mimetic” in this setting, even in a narrowly metabolic sense.
Another uncertainty involves safety and off-target effects. Metformin is generally considered safe and is widely prescribed for type 2 diabetes, but its use in oncology populations often intersects with other medications, organ function changes, and treatment-related toxicities. The BIMET-1 trial reported tolerability within its predefined criteria, yet the specific relationship between Lac-Phe elevation and any adverse events has not been dissected. It is not known, for instance, whether patients with the highest Lac-Phe levels experience different side-effect profiles or metabolic shifts compared with those whose Lac-Phe rises more modestly.
How to read the evidence
The strength of this story rests on a chain of peer-reviewed primary sources, each contributing a distinct link. The 2022 Nature paper provides the foundational biology: Lac-Phe is real, it rises with exercise, and it affects feeding behavior in controlled experiments. The Nature Metabolism study extends that finding to metformin in humans, showing the drug can raise the same metabolite under defined conditions. The EMBO Molecular Medicine paper then applies that observation to a specific clinical population, prostate cancer patients in a randomized trial. Each step is individually well-sourced, with raw data accessible through major repositories such as the National Library of Medicine and related archive services that host underlying datasets and supplementary materials.
Readers should, however, distinguish between correlation and mechanism. The studies show that metformin treatment is associated with higher Lac-Phe. They do not prove that Lac-Phe is the reason metformin might benefit cancer patients, nor do they establish that deliberately manipulating Lac-Phe would reproduce all of metformin’s effects. Metformin has many documented actions on mitochondrial function, glucose metabolism, and cellular signaling, any of which could influence cancer biology independently of Lac-Phe. The current evidence supports Lac-Phe as one plausible piece of a larger metabolic puzzle rather than a singular explanation.
It is also important to recognize the difference between surrogate markers and patient-centered outcomes. Lac-Phe is a biochemical readout that can be measured precisely in blood, but patients and clinicians ultimately care about fatigue, weight gain, cardiovascular risk, quality of life, and survival. Until trials are designed to connect Lac-Phe changes with those concrete endpoints, the metabolite should be viewed as an intriguing signal, not a stand-alone therapeutic target. Future studies might, for example, stratify patients by Lac-Phe response and track whether those strata align with better weight control or fewer metabolic complications during hormone therapy.
For those interested in exploring the primary literature further, bibliographic tools such as MyNCBI can help organize citation trails, while curated bibliography collections make it easier to follow related work on metformin, exercise physiology, and cancer metabolism. These resources, combined with the trial report, metabolomics analyses, and experimental studies already in the public domain, provide a transparent framework for evaluating new claims as they emerge.
In practical terms, the current data do not justify changing standard prostate cancer treatment solely to chase higher Lac-Phe levels. Instead, they highlight a promising research direction: using a well-known diabetes drug to modulate exercise-linked metabolites in patients who may struggle to exercise. As larger, more definitive trials are designed (ideally incorporating both metabolic markers and robust clinical endpoints), clinicians and patients will gain clearer guidance on whether this biochemical signal can be translated into tangible benefits during the demanding course of hormone therapy.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
